In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa | Zendy

João Pires | Zendy; Thissa N. Siriwardena | Zendy; Michaela Stach | Zendy; Regula Tinguely | Zendy; Sara Kasraian | Zendy; Francesco Luzzaro | Zendy; Stephen L. Leib | Zendy; Tamis Darbre | Zendy; JeanLouis Reymond | Zendy; Andrea Endimiani | Zendy

Open Access

In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Author(s) -

João Pires,

Thissa N. Siriwardena,

Michaela Stach,

Regula Tinguely,

Sara Kasraian,

Francesco Luzzaro,

Stephen L. Leib,

Tamis Darbre,

JeanLouis Reymond,

Andrea Endimiani

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01853-15

Subject(s) - acinetobacter baumannii , pseudomonas aeruginosa , microbiology and biotechnology , antimicrobial , multiple drug resistance , antibiotics , biology , in vitro , antibacterial activity , acinetobacter , chemistry , bacteria , biochemistry , genetics

The in vitro activity of the novel antimicrobial peptide dendrimer G3KL was evaluated against 32 Acinetobacter baumannii (including 10 OXA-23, 7 OXA-24, and 11 OXA-58 carbapenemase producers) and 35 Pseudomonas aeruginosa (including 18 VIM and 3 IMP carbapenemase producers) strains and compared to the activities of standard antibiotics. Overall, both species collections showed MIC50/90 values of 8/8 μg/ml and minimum bactericidal concentrations at which 50% or 90% of strains tested are killed (MBC50/90) of 8/8 μg/ml. G3KL is a promising molecule with antibacterial activity against multidrug-resistant and extensively drug-resistant A. baumannii and P. aeruginosa isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research